Figure 4.

Change in chemokine and cytokine expression within tumors from mice receiving ACT in response to PD-1 blockade. (A) Chemokine mRNA levels within the tumor site from mice infused with pmel-1 T cells with or without PD-1 blockade. Mice challenged with 5×10⁵ B16 cells received pmel-1 T cells on day 7, then treated with either anti-PD-1 antibody or control antibody on days 7, 9 and 11 and sacrificed on day 13. RNA was isolated from the tumor tissues of mice (N=3 for each group). The expression levels of chemokine within tumors were analyzed by realtime PCR. (B) Representative plot of CXCL10-producing cells within tumor tissue. (C) Representative histogram plots of CXCL10 production within tumor tissue from mice treated with ACT and anti-PD-1, as well as from mice treated with ACT with control antibody, were shown after gating with CD11b⁺ subsets. (D) Percentage of CXCL10-producing cells in CD11b⁺ cells within tumor tissue from mice treated with ACT and anti-PD-1, as well as from mice treated with ACT with control antibody (N=3-5 per group). (E) Cytokine mRNA levels within the tumor site from mice infused with pmel-1 T cells with or without PD-1 blockade. (** indicates P<0.01)